David Lebovitz
Stock Analyst at Citigroup
(3.23)
# 1,047
Out of 4,711 analysts
91
Total ratings
66.13%
Success rate
7.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $53.60 | +38.06% | 2 | Nov 14, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $93 → $81 | $65.66 | +23.36% | 2 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $382 → $371 | $308.44 | +20.28% | 3 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $291 → $342 | $245.44 | +39.34% | 30 | Aug 2, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $41.51 | -8.46% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $46.24 | -63.24% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $90.14 | +2.06% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $56.12 | -3.78% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $35.63 | -1.77% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $3.18 | +434.59% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $4.45 | +147.19% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $136.38 | +45.92% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $32 | $0.64 | +4,939.37% | 2 | Nov 3, 2020 |
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $53.60
Upside: +38.06%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Neutral
Price Target: $93 → $81
Current: $65.66
Upside: +23.36%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $382 → $371
Current: $308.44
Upside: +20.28%
Alnylam Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $291 → $342
Current: $245.44
Upside: +39.34%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $41.51
Upside: -8.46%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $46.24
Upside: -63.24%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $90.14
Upside: +2.06%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $56.12
Upside: -3.78%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $35.63
Upside: -1.77%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $3.18
Upside: +434.59%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $4.45
Upside: +147.19%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $136.38
Upside: +45.92%
Nov 3, 2020
Maintains: Overweight
Price Target: $34 → $32
Current: $0.64
Upside: +4,939.37%